Sanofi (SNY.US) faces another setback in research and development: Rare disease drug Phase III trial halted after failure, new CEO under pressure.

According to Zhitong Finance and Economics APP, French pharmaceutical giant Sanofi (SNY.US) announced on Wednesday that it will prematurely terminate a study because an experimental drug targeting a rare autoimmune disease did not show effectiveness in late-stage clinical trials. This latest setback further increases the operational pressure faced by recently appointed CEO Beln Garijo.